HuidaGene Therapeutics is advancing HG202, a CRISPR-Cas13 RNA-editing therapy targeting VEGFA, aimed at treating neovascular age-related macular degeneration (nAMD). This asset addresses a significant unmet need in the nAMD market, particularly for patients who are either responsive or non-responsive to existing anti-VEGF therapies. The potential for a one-time treatment to reduce the burden of frequent intravitreal injections could enhance patient compliance and satisfaction, positioning HG202 favorably against current therapies. The nAMD market is projected to grow significantly, driven by an aging population and increasing prevalence of the disease. However, competition remains robust with established anti-VEGF therapies and emerging gene therapies. Diligence should focus on regulatory pathways and potential reimbursement challenges, given the innovative nature of the therapy.